CannaPacific

CannaPacific is an Australian biotech company focused on the cannabinoid pharmaceutical sector. Our medical team is headed by Dr Mike Fay, a leading Oncologist and Dr Erica Cameron-Taylor, a Palliative Care Specialist. Our agricultural R&D is headed by Plant Scientist Professor Chris Grof and Tim Bowser, a former executive from the Australian opiate industry. Both are highly experienced in genomic-based molecular breeding of medicinal plants for the production of pharmaceutical actives. Our equity partner, Aleafia Health Inc, is Canada’s largest medical cannabis clinical network with a 10 million point medical cannabis dataset. Aleafia Health Inc educational network includes 900+ Canadian MDs and Nurse Practitioners and over 70,000 Patients. Aleafia Health manufactures medicinal cannabis products for CannaPacific for supply to the Australian market as unregistered medicines under a Special Access Scheme. CannaPacific has engaged internationally recognised service and technology providers for the development of registered cannabinoid-based medicines. CannaPacific is licenced by the Australian Government to cultivate and research medicinal cannabis. CannaPacific owns a 10,000 sqm Dutch glasshouses near Byron Bay, NSW with a retrofit program underway to optimise operations for the cultivation of medical cannabis to GACP & GMP Standards.